We claim:

- A method for the prophylactic treatment of a subject whose blood has undergone extracorporeal circulation, wherein an effective amount of an anticoagulant agent is administered to said subject.
- A method as claimed in claim 1, for the prophylaxis of
 vascular complications after the extracorporeal circulation.
 - 3. A method for treating a subject with extracorporeal circulation, wherein an effective amount of an anticoagulant agent is administered to said subject for effective
- anticoagulant protection during the extracorporeal circulation and for prophylaxis of vascular complications after the extracorporeal circulation.
- A method as claimed in claims 1 or 3, wherein the
 anticoagulant agent has a terminal half-life of at least about 4 hours.
 - 5. A method as claimed in claim 4, wherein the anticoagulant agent has an enduring pharmacodynamic activity.
 - 6. A method as claimed in claims 1 or 3, wherein PEG-hirudin is administered.
- A method as claimed in claims 1 or 3, for treating a subject
 with chronic renal insufficiency requiring regular hemodialysis.
- A method as claimed in claim 7, wherein the anticoagulant agent is administered in the form of a single dose per hemodialysis.
 - 9. A method as claimed in claim 8, wherein the single dose is administered at the start of a hemodialysis.
- 40 10. A method as claimed in claim 8 or 9, wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged about 2.7-fold to about 1.8-fold during the hemodialysis.

25

+49 89 987304

2

11. A method as claimed in any of claims 8 to 10, wherein the amount of the single dose administered for a hemodialysis is such that the APTT is prolonged at least about 1.2-fold until the next hemodialysis.

5

10

15

offices of the Sant Storie Storie

4 R mill for 8 H B B H

 20

25

30

35

40